{"pmid":32029004,"pmcid":"PMC7003341","title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","text":["A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.","Mil Med Res","Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan","32029004"],"abstract":["In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV."],"journal":"Mil Med Res","authors":["Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan"],"date":"2020-02-08T11:00:00Z","year":2020,"_id":"32029004","week":"20206|Feb 03 - Feb 09","doi":"10.1186/s40779-020-0233-6","keywords":["2019 novel coronavirus","2019-nCoV","Clinical practice guideline","Evidence-based medicine","Infectious diseases","Pneumonia","Rapid advice guideline","Respiratory disease"],"source":"PubMed","locations":["Chinese","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647052791808,"score":6.7365713,"similar":[{"pmid":32098466,"title":"[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","text":["[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases.","Zhonghua Jie He He Hu Xi Za Zhi","Shi, Y","32098466"],"abstract":["Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Shi, Y"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32098466","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200225-00183","keywords":["Military","diagnosis and treatment","infection","medical team","novel coronavirus"],"source":"PubMed","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647462785024,"score":190.91444},{"pmid":32057212,"title":"[Recommendations for general surgery clinical practice in novel coronavirus pneumonia situation].","text":["[Recommendations for general surgery clinical practice in novel coronavirus pneumonia situation].","Novel coronavirus pneumonia (NCP) is a highly infectious disease, has a long incubation period and a variety of clinical manifestations, which has a significant impact on public health and life. Afterwards, scientific and standardized work processing during the epidemic is of great significance for prevention and control. In order to implement the central government's decision-making deployment and defeat the NCP as soon as possible, we had focused on the key points in the clinical work of general surgery according to latest relevant guidelines, literature and experience in epidemic prevention. Finally, we drafted the prevention and control strategies and recommendations to make a reference for medical staff of general surgery to fight NCP.","Zhonghua Wai Ke Za Zhi","Tao, K X","Zhang, B X","Zhang, P","Zhu, P","Wang, G B","Chen, X P","32057212"],"abstract":["Novel coronavirus pneumonia (NCP) is a highly infectious disease, has a long incubation period and a variety of clinical manifestations, which has a significant impact on public health and life. Afterwards, scientific and standardized work processing during the epidemic is of great significance for prevention and control. In order to implement the central government's decision-making deployment and defeat the NCP as soon as possible, we had focused on the key points in the clinical work of general surgery according to latest relevant guidelines, literature and experience in epidemic prevention. Finally, we drafted the prevention and control strategies and recommendations to make a reference for medical staff of general surgery to fight NCP."],"journal":"Zhonghua Wai Ke Za Zhi","authors":["Tao, K X","Zhang, B X","Zhang, P","Zhu, P","Wang, G B","Chen, X P"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32057212","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.0529-5815.2020.0001","keywords":["2019-nCoV","Diagnosis","General Surgery","Pneumonia","Prevention and control","Treatment"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647287672832,"score":187.2393},{"pmid":32023681,"title":"[Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)].","text":["[Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)].","Since December 2019, China has been experiencing an outbreak of new infectious disease caused by 2019 novel coronavirus (2019-nCoV). The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray. China rapidly identified 2019-nCoV-related pneumonia a statutory infectious disease. To standardize the diagnosis and treatment of this new infectious disease, operational guidelines for the diagnosis and management of 2019-nCoV infection is accomplished by Peking Union Medical College Hospital.","Zhonghua Nei Ke Za Zhi","32023681"],"abstract":["Since December 2019, China has been experiencing an outbreak of new infectious disease caused by 2019 novel coronavirus (2019-nCoV). The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray. China rapidly identified 2019-nCoV-related pneumonia a statutory infectious disease. To standardize the diagnosis and treatment of this new infectious disease, operational guidelines for the diagnosis and management of 2019-nCoV infection is accomplished by Peking Union Medical College Hospital."],"journal":"Zhonghua Nei Ke Za Zhi","date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023681","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0578-1426.2020.03.003","keywords":["Diagnosis","Management","Novel coronavirus","Pneumonia"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647034966016,"score":185.57281},{"pmid":32033513,"title":"[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","text":["[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together.","Zhonghua Yi Xue Za Zhi","Lin, L","Li, T S","32033513"],"abstract":["the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together."],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Lin, L","Li, T S"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32033513","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0376-2491.2020.0001","keywords":["2019 Novel coronavirus","guidelines","pneumonia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647055937536,"score":183.93668},{"pmid":32164424,"title":"COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.","text":["COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.","As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.","Am J Chin Med","Chan, Kam Wa","Wong, Vivian Taam","Tang, Sydney Chi Wai","32164424"],"abstract":["As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19."],"journal":"Am J Chin Med","authors":["Chan, Kam Wa","Wong, Vivian Taam","Tang, Sydney Chi Wai"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32164424","week":"202011|Mar 09 - Mar 15","doi":"10.1142/S0192415X20500378","keywords":["2019-nCoV","COVID-19","Chinese Medicine","Guideline","Integrative Medicine","Review"],"source":"PubMed","locations":["Chinese","H1N1","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647946178560,"score":179.06346}]}